Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvoxamine SCHEMBL5569574 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL33983 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL178609 | 1.00 | SLC6A4 (1.00) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL8674929 | 0.99 | SLC6A4 (0.98) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5960517 | 0.99 | SLC6A4 (0.98) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL27816994 | 0.98 | SLC6A4 (0.95) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13090665 | 0.96 | SLC6A4 (0.93) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL5508120 | 0.94 | SLC6A4 (0.89) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Fluvoxamine SCHEMBL30628144 | 0.92 | SLC6A4 (0.84) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17702850 | 0.91 | SLC6A4 (0.84) | SLC6A4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | claimed |
| US-4085225-A | Oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-18 | — | — | US | claimed |
| US-12611387-B2 | Compound and composition for inducing neuroprotection | REST THERAPEUTICS (FR) | 2026-04-28 | — | — | US | disclosed |
| EP-4687890-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4661017-A1 | MENTAL ILLNESS DIAGNOSIS AND DRUG RECOMMENDATION METHOD | Samsung Life Public Welfare Foundation (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250319069-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BIOXCEL THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250177770-A1 | SUBSTANCE USE DISORDER PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | ACTIPULSE NEUROSCIENCE INC (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119613319-A | Compositions comprising benzoates of 5-methoxy-N, N-dimethyltryptamine | 贝克利心理科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-116056762-B | Compositions comprising benzoates of 5-methoxy-N, N-dimethyltryptamine | 贝克利心理科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024211911-A1 | METHODS FOR TREATING DEPRESSIVE STATES | OAKTREE FUND ADMINISTRATION, LLC (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-0919234-A2 | Potentiation of pharmaceuticals by moxonidine | ELI LILLY AND COMPANY (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5776969-A | MIXTURE OF ANTISEROTONIN AGENT AND SEROTONIN RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0830864-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY (US) | 1998-03-25 | — | — | EP | disclosed |
| EP-0792649-A1 | Treatment of sleep disorders | ELI LILLY AND COMPANY (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0759299-A1 | Potentiation of serotonin response | ELI LILLY AND COMPANY (US) | 1997-02-26 | — | — | EP | disclosed |
| EP-0747049-A1 | Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis | ELI LILLY AND COMPANY (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1996024353-A1 | METHODS OF TREATING OR PREVENTING PSYCHIATRIC DISORDERS | ELI LILLY AND COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0714663-A2 | Potentiation of drug response by a serotonin 1A receptor antagonist | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| US-4085225-A | Oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611387-B2 | Compound and composition for inducing neuroprotection | GAP43, BDNF, NEFM | SLC6A4 1101/4885CYP1A2 2314/4885CYP3A4 3864/4885 |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRL1 | SLC6A4 466/4885CYP1A2 896/4885CYP3A4 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.